A new study published this month in the journal Molecular Cancer Therapeutics, and published online by the National Institute of Health, has found that the cannabis compounds cannabidiol (CBD) and tetrahydrocannabinol (THC) enhance the anticancer effects of radiation in an orthotopic murine glioma model.
According to the study; “High-grade glioma is one of the most aggressive cancers in adult humans and long-term survival rates are very low as standard treatments for glioma remain largely unsuccessful. Cannabinoids have been shown to specifically inhibit glioma growth as well as neutralize oncogenic processes such as angiogenesis.
In an attempt to improve treatment outcome, we have investigated the effect of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) both alone and in combination with radiotherapy in a number of glioma cell lines (T98G, U87MG, and GL261).”
After conducted the study, researchers conclude; “Our data highlight the possibility that these cannabinoids can prime glioma cells to respond better to ionizing radiation, and suggest a potential clinical benefit for glioma patients by using these two treatment modalities.”
The study, conducted by researchers at the University of London, can be found by clicking here.